GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Vision SA (FRA:G09) » Definitions » Asset Turnover

Genomic Vision (FRA:G09) Asset Turnover : 0.18 (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Genomic Vision Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Genomic Vision's Revenue for the six months ended in Jun. 2023 was €0.82 Mil. Genomic Vision's Total Assets for the quarter that ended in Jun. 2023 was €4.47 Mil. Therefore, Genomic Vision's Asset Turnover for the quarter that ended in Jun. 2023 was 0.18.

Asset Turnover is linked to ROE % through Du Pont Formula. Genomic Vision's annualized ROE % for the quarter that ended in Jun. 2023 was 630.70%. It is also linked to ROA % through Du Pont Formula. Genomic Vision's annualized ROA % for the quarter that ended in Jun. 2023 was -286.16%.


Genomic Vision Asset Turnover Historical Data

The historical data trend for Genomic Vision's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Vision Asset Turnover Chart

Genomic Vision Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.31 0.20 0.20 0.25

Genomic Vision Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.10 0.13 0.15 0.18

Competitive Comparison of Genomic Vision's Asset Turnover

For the Diagnostics & Research subindustry, Genomic Vision's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomic Vision's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genomic Vision's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Genomic Vision's Asset Turnover falls into.



Genomic Vision Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Genomic Vision's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=1.48/( (6.771+4.989)/ 2 )
=1.48/5.88
=0.25

Genomic Vision's Asset Turnover for the quarter that ended in Jun. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=0.82/( (4.989+3.957)/ 2 )
=0.82/4.473
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Genomic Vision  (FRA:G09) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Genomic Vision's annulized ROE % for the quarter that ended in Jun. 2023 is

ROE %**(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-12.8/-2.0295
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-12.8 / 1.64)*(1.64 / 4.473)*(4.473/ -2.0295)
=Net Margin %*Asset Turnover*Equity Multiplier
=-780.49 %*0.3666*-2.204
=ROA %*Equity Multiplier
=-286.16 %*-2.204
=630.70 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Genomic Vision's annulized ROA % for the quarter that ended in Jun. 2023 is

ROA %(Q: Jun. 2023 )
=Net Income/Total Assets
=-12.8/4.473
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-12.8 / 1.64)*(1.64 / 4.473)
=Net Margin %*Asset Turnover
=-780.49 %*0.3666
=-286.16 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Genomic Vision Asset Turnover Related Terms

Thank you for viewing the detailed overview of Genomic Vision's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomic Vision (FRA:G09) Business Description

Traded in Other Exchanges
N/A
Address
80-84 rue des Meuniers, Green Square, Batiment E, Bagneux, FRA, 92220
Genomic Vision SA is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics.

Genomic Vision (FRA:G09) Headlines

No Headlines